Recordati Industria Chimica e Farmaceutica

RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2025)

Milan, 31st July 2025 – Please be informed that the Interim Report First Half as at 30th June 2025, approved on 29th July 2025 by the Board of Directors, as per the press release issued on the same date, to which reference is made, is available to the public, together with the Independent Auditors' Report on the interim consolidated financial statements as at 30th June 2025, as of today, at the Company's registered office, on the Company's website and on the "" storage mechanism.

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz +44 7824 394 750 [email protected] Gianluca Saletta +39 348 979 4876 [email protected]

Media Relations

ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [email protected] UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [email protected]